Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel-Group, Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of the Safety and Efficacy of Oral AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy

NCT07680322 is registered in ClinicalTrials.gov with Aeovian Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07680322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07680322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel-Group, Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of the Safety and Efficacy of Oral AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy
Lead sponsor
Aeovian Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
December 21, 2027
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy, tuberous sclerosis complex